A case of pathological complete regression in combined modality treatment of resectable Her2/neu-positive gastric cancer
| Autor: | A. V. Avgustinovich, S. G. Afanasyev, L. V. Spirina, E. V. Kaygorodova, R. V. Ermolenko, E. N. Samtsov, I. G. Frolova, O. V. Cheremisina |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Сибирский онкологический журнал, Vol 23, Iss 1, Pp 170-177 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1814-4861 2312-3168 |
| DOI: | 10.21294/1814-4861-2024-23-1-170-177 |
| Popis: | Background. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality treatment including 8 cycles of neoadjuvant chemotherapy with mFLOT + trastuzumab followed by R0 resection. The addition of targeted therapy did not have a negative impact on the perioperative period. Histolohical examination of the surgical specimen revealed pathological complete response (Mandart TGR1). Currently, the patient has been followed-up for 27 months without signs of disease relapse. Conclusion. Total neoadjuvant chemotherapy with mFLОТ+ trastuzumab for operable gastric cancer with Her2/neu overexpression allows us to hope for improved long-term treatment outcomes. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|